Skip to main content
. Author manuscript; available in PMC: 2014 Sep 15.
Published in final edited form as: J Immunol. 2013 Aug 16;191(6):3082–3089. doi: 10.4049/jimmunol.1300830

Figure 5. CTLA4Ig is ineffective in SMAD3-deficient mice.

Figure 5

Wild type or SMAD3-deficient mice were sensitized with OVA and given an inhaled challenge with either OVA or HEL. CTLA4Ig was administered to groups of mice as indicated and samples were collected 72 hours after challenge. Each experimental group consisted of 5 mice and has been repeated 3 times. Shown is data from one representative experiment. * = p< 0.05 as compared to OVA primed and challenged without CTLA4Ig as determined by Kruskall-Wallis with Dunns post test comparisons.